Submitted for Publication: January 6, 2014; final revision received April 6, 2014; accepted May 16, 2014.
Published Online: August 27, 2014. doi:10.1001/jamapsychiatry.2014.1060.
Study concept and design: Lautner, Wallin, Minthon, Blennow, Zetterberg, Hansson.
Acquisition, analysis, or interpretation of data: Lautner, Palmqvist, Mattsson, Andreasson, Wallin, Pålsson, Jakobsson, Herukka, Owenius, Olsson, Hampel, Rujescu, Ewers, Landén, Zetterberg, Hansson.
Drafting of the manuscript: Lautner, Hampel, Zetterberg, Hansson.
Critical revision of the manuscript for important intellectual content: Lautner, Palmqvist, Mattsson, Andreasson, Wallin, Pålsson, Jakobsson, Herukka, Owenius, Olsson, Hampel, Rujescu, Ewers, Landén, Minthon, Blennow.
Statistical analysis: Lautner, Mattsson, Andreasson, Owenius, Ewers.
Obtained funding: Wallin, Owenius, Rujescu, Landén, Blennow, Zetterberg, Hansson.
Administrative, technical, or material support: Hampel, Rujescu, Landén, Minthon.
Study supervision: Palmqvist, Rujescu, Blennow, Zetterberg, Hansson.
Conflict of Interest Disclosures: Dr Hampel has received lecture honoraria, research grants, travel funding, participated in scientific advisory boards, and served as a consultant to diagnostic, biotechnology, and pharmaceutical companies involved in the manufacture and marketing of biomarkers, diagnostics, drugs, or medicinal products for cognitive impairment and Alzheimer disease, including Boehringer-Ingelheim, Bristol-Myers Squibb, Elan Corporation, Wyeth, Novartis, Eisai Inc, Pfizer, Schwabe, sanofi-aventis, Roche Pharmaceuticals and Diagnostics, GE Healthcare, AstraZeneca, Avid, Eli Lilly & Company, Janssen-Cilag, Merz Pharmaceuticals, GlaxoSmithKline-Biologicals, Jung-Diagnostics, Thermo Fisher Scientific Clinical Diagnostics, and Cytox during the last 2 years (2011-2013); he is also a coinventor in pending patent submissions relating to biological markers and/or diagnostics. Dr Landén has received compensation for lectures from AstraZeneca, Bayer, Biophausia, Bristol-Myers Squibb, Lundbeck Pharmaceuticals, Eli Lilly Sweden, Wyeth, and Servier Sweden and served on the advisory boards for AstraZeneca and Lundbeck Pharmaceuticals during the past 3 years. Dr Blennow has served on the advisory boards for Pfizer, Roche, Eli Lilly & Company, and Innogenetics. No other disclosures were reported.
Funding/Support: Work in the authors’ laboratory is funded by grant 14002 from the Swedish Research Council and grants from the European Research Council (cohort C), the Crafoord Foundation, the Swedish Brain Foundation, the Göteborg Medical Society, the Skåne University Hospital Foundation, the Johan and Jakob Söderberg’s Foundation, the Swedish Alzheimer Association, the Swedish federal government under the Läkarutbildningsavtalet/Avtalet om läkarutbildning och medicinsk forskning agreement, Swedish Brain Power, the Strategic Research Area MultiPark (Multidisciplinary Research in Parkinson’s disease) at Lund University, and the Knut and Alice Wallenberg Foundation. Injection doses of [18F]flutemetamol were sponsored by GE Healthcare. This study was also supported by the Katharina-Hardt-Foundation, Bad Homburg vor der Höhe, Germany, and the Fondation Pour La Recherche Sur Alzheimer, Paris (Dr Hampel). Part of the data collection and sharing for this project (data used in the replication of cohort C) was funded by grant U01 AG024904 from the National Institutes of Health (ADNI) and award W81XWH-12-2-0012 from the Department of Defense (DOD) (DOD ADNI). The ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and generous contributions from Alzheimer’s Association, Alzheimer’s Drug Discovery Foundation, BioClinica, Inc, Biogen Idec, Inc, Bristol-Myers Squibb Company, Eisai, Inc, Elan Pharmaceuticals, Inc, Eli Lilly and Company, F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc, GE Healthcare, Innogenetics, NV, IXICO Ltd, Janssen Alzheimer Immunotherapy Research & Development, LLC, Johnson & Johnson Pharmaceutical Research & Development, LLC, Medpace, Inc, Merck & Co, Inc, Meso Scale Diagnostics, LLC, NeuroRx Research, Novartis Pharmaceuticals Corporation, Pfizer Inc, Piramal Imaging, Servier, Synarc, Inc, and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research supports ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Disease Cooperative Study at the University of California, San Diego.
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication, with the following exception. Part of the data used in preparation of this article was obtained from the ADNI database (http://adni.loni.usc.edu); as such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report.
Additional Contributions: Neuropsychologist Susanna Vestberg, PhD, Department of Psychology, Lund University, Sweden, assisted with characterizing cohort C regarding the cognitive status and did not receive any compensation for this work. The ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles.